

U.S. DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

Art Unit 125 908,597 et al., SJFriedman 05/22/78 Geørge P. Casten

MAILED

FEB 1 6 1979

	Mead Johnson & Com.	GROUP 120
	2404 Penn. Ave.	THIS IS A COMMUNICATION FROM THE EXAMINER
	Evansville, Ind. 47721	IN CHARGE OF YOUR APPLICATION.
		COMMISSIONER OF
		PATENTS AND TRADEMARKS
	mis application has been examined.	
	Responsive to communication filed on	79
	<u> </u>	- / · ·
	This action is made final.	2
	A SHORTENED STATUTORY PERIOD FOR RESPONSE TO THIS	ACTION IS SET TO EXPIRE MONTH(S)
	DAYS FROM THE DATE OF THIS LETTER.	
	FAILURE TO RESPOND WITHIN THE PERIOD FOR RESPONSE W	THE CALLET THE ARREST ATION TO RECOME ARANDONED
	FAILURE TO RESPOND WITHIN THE PERIOD FOR RESPONSE W	35 U.S.C. 133
PART I	THE FOLLOWING ATTACHMENT(S) ARE PART OF THIS	ACTION:
	1. Notice of References Cited, Form PTO-892.	2. Notice of Informal Patent Drawing, PTO-948.
	3. Notice of Informal Patent Application,	4.
	Form PTO-152	
PART 1	I SUMMARY OF ACTION	
· ARI ·	. 6	
	1. Claims	are pending in the application.
	*	
	Of the above, claims	are withdrawn from consideration.
	2. Claims	have been cancelled.
	3. C //aims	are allowed.
	1 174 Claims 1-9	
	4. 1 Claims /	are rejected.
	5. Claims	are objected to.
÷	6. Claims	are subject to restriction or election requirement.
	7. The formal drawings filed on	are acceptable.
	O The drawing assessment of the don	has been
	8. The drawing correction request filed on	—
		disapproved.
	9. Acknowledgement is made of the claim for priority	under 35 U.S.C. 119. The certified copy has
	been received.	been filed in parent application:
	not been received.	serial no filed on
		or allowance except for formal matters, prosecution as to the
	merits is closed in accordance with the practice u	nder Ex parte Quayle, 1935 C.D. 11; 453 OG. 213.
	11. Other	

All the claims are rejected as being based on new matter under 35 USC 132. "Neuroleptically in-effective dose" does not find proper basis in the original disclosure and should be deleted. Page 6 merely states "without neuroleptic effect in a psychotic patient". The claims relate to a neurotic patient.

Stanlay J. Friedman Primary Examiner Group Art Unit 125

SJFriedman/baf A/C⁻703 557-2575